CA-NEXON-AMERICA
7.6.2022 15:03:34 CEST | Business Wire | Press release
MapleStory , Nexon ’s original free-to-play, side scrolling 2D MMORPG with an aggressively cute game style, announces the first of its two-part summer update, “Destiny: Remastered,” lands in-game on June 15, filled to the brim with special events, a revamp of all of Explorer jobs, plus a gift package for pre-registering before June 13!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005606/en/
SPECIAL EVENTS
Summer just wouldn’t be summer in MapleStory
without some special, in-game events! It’s time for the season of music and majesty, as new friend Stella comes to experience Maple World first hand. There are a wealth of rewards to collect during the musical summer nights of Starlight Symphony
, plus the return of Tera Burning Plus
and Burning World
. On top of all that, pre-register a character (must be level 61 or above) before 11am PDT on June 13 to get a special Destiny gift package featuring Lil Symphony pets, Angelic Alphabet Damage Skin, a heap of Melody Coins to get a head start in Starlight Symphony, and a Magician of the Sacred Forest outfit!
EXPLORER REVAMP
The Explorer class of characters in MapleStory
has been the backbone of the game for the last seventeen years. These 14 unique Explorer jobs are receiving a complete overhaul of animations, improved skills, new story segments, and more.
The Explorer revamp benefits the following characters:
- Warrior : Hero, Paladin, Dark Knight
- Magician : Arch Mage (Fire/Poison), Arch Mage (Ice/Lightning), Bishop
- Bowman : Bowmaster, Marksman
- Thief : Night Lord, Shadower, Dual Blade
- Pirate : Corsair, Buccaneer, Cannoneer
IMPROVEMENTS GALORE
Incorporated into the “Destiny: Remastered” update are additional improvements, new boss accessories, and boss difficulties so everyone can enjoy a better Maple experience:
- No more Mastery Books ! - Mastery Books are no longer needed to upgrade 4th Job skills.
- Dawn Boss Accessories set - Claim a new set of accessories from bosses to forge a powerful new set.
- New Boss Difficulties - Take on Chosen Seren and Verus Hilla on normal mode and overcome Will on easy difficulty.
BEAN BRIGADE “DESTINY: REMASTERED” SNEAK PEEK
Members of MapleStory
’s content creator program, Bean Brigade
, will be jumping into the test servers early beginning today to give Maplers a sneak peek of all the exciting changes and updates coming to “Destiny: Remastered.” Follow along on Bean Brigade’s dedicated Twitch page
from June 7 through 10.
SUMMER UPDATE PART TWO
Last but not least, Summer Update Part Two, “Destiny: Homecoming,” arrives on July 20
with an all-new homestead feature allowing Maplers to purchase and decorate their very own home! Show off your exquisite taste and home decorating style, and be the envy of every other homeowner in Maple World. Also in Part Two, the Watcher Kalos awaits on top of Karote, the Unending Tower. Win in the battle against this formidable boss to obtain a new Eternal Equipment Set!
Grab your sunscreen and check out everything there is to do in MapleStory this summer!
Assets: HERE
Social Media: Twitch / Facebook / Twitter / YouTube / Website
About MapleStory
https://maplestory.nexon.net
MapleStory
is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory
services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 17 years ago. There have been over 274 million characters created to date, which would make MapleStory
’s Maple World the 4th highest populated country in the world.
About Nexon America Inc.
https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory
and Mabinogi
for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005606/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom